Log In
BCIQ
Print this Print this
 

OPX-212

  Manage Alerts
Collapse Summary General Information
Company Opexa Therapeutics Inc.
DescriptionAutologous T-cell immunotherapy targeting aquaporin-4 (AQP4)
Molecular Target Aquaporin-4 (AQP4)
Mechanism of ActionCell therapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat neuromyelitis optica (NMO)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today